ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Umoja Biopharma launches with $53 million for drug-controlled CAR T-cell therapies

by Ryan Cross
November 21, 2020 | APPEARED IN VOLUME 98, ISSUE 45

 

Umoja Biopharma has launched with $53 million in series A financing to develop next-generation CAR T-cell immunotherapies for cancer. Umoja says it has three tricks for improving cell therapies: genetically engineering T cells inside the body rather than outside; using “tumor tags” to label cancer cells for T cells to attack; and using small molecules to change the T cells’ activity. Umoja was cofounded by Seattle Children’s cancer researcher Michael Jensen and Purdue University chemist Philip Low. Low also cofounded the cancer firm Endocyte, which Novartis acquired for $2.1 billion in 2018.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment